

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) A method for treating ~~a condition in an animal or human subject, said condition comprising an involuntary muscle contraction wherein said method comprises a step of administering a Clostridium neurotoxin component to said subject using a needleless syringe~~ a wrinkle in a human subject, the method comprising the step of administering an amount of a botulinum toxin to the human subject using a needleless syringe, the amount of the botulinum toxin being effective to treat the wrinkle by reducing a muscle contraction.

2. (Currently amended) The method of claim 1 wherein ~~said neurotoxin component~~ the botulinum toxin is administered with a carrier.

3. (Currently amended) The method of claim 2 wherein ~~said neurotoxin component~~ the botulinum toxin is coated on said carrier.

4. (Currently amended) The method of claim 2 wherein said carrier comprises a dense, preferably solid ~~and/or~~ or metallic, material selected from the group consisting of gold, platinum, tungsten and ice crystal.

5. (Cancelled)

6. (Currently amended) The method of claim 1 wherein ~~said neurotoxin component~~ the botulinum toxin is administered to a skin of said subject.

7. (Currently amended) The method of claim 1 wherein ~~said neurotoxin component~~ the botulinum toxin is administered to one or more layers of a skin of said subject where a nerve is located.

8. (Cancelled)

9. (Currently amended) The method of claim 1 wherein ~~said neurotoxin component~~ the botulinum toxin is administered to a muscle tissue of said subject.

10. (Currently amended) The method of claim 1, wherein ~~said neurotoxin component is selected from the group consisting of diffieile toxin or a variant thereof, a butyricum toxin or a variant thereof, a tetani toxin or a variant thereof, and a botulimum toxin types A, B, C1, D, E, F, G, or a variant thereof~~ the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F, and G.

11. (Cancelled)

12. (Currently amended) The method of claim 1 wherein ~~said neurotoxin component~~ the botulinum toxin is botulinum toxin type A.

13-35. (Cancelled)

36. (New) A method for treating brow furrows in a human subject, the method comprising the step of administering an amount of a botulinum toxin to the human subject using a needleless syringe, the amount of the botulinum toxin being effective to treat a brow furrow by reducing a muscle contraction.

37. (New) The method of claim 36, wherein the botulinum toxin is administered with a carrier.

38. (New) The method of claim 37, wherein the botulinum toxin is coated on said carrier.

39. (New) The method of claim 37, wherein said carrier comprises a dense, preferably solid or metallic, material selected from the group consisting of gold, platinum, tungsten and ice crystal.

40. (New) The method of claim 36, wherein the botulinum toxin is administered to a skin of said subject.

41. (New) The method of claim 36, wherein the botulinum toxin is administered to one or more layers of a skin of said subject where a nerve is located.

42. (New) The method of claim 36, wherein the botulinum toxin is administered to a muscle tissue of said subject.

43. (New) The method of claim 36, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F, and G.

44. (New) The method of claim 36, wherein the botulinum toxin is botulinum toxin type A.